FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4286563749> ?p ?o ?g. }

• W4286563749 endingPage "672" @default.
• W4286563749 startingPage "649" @default.
• W4286563749 abstract "New drug approvals in the United States must be supported by substantial evidence from adequate and well-controlled trials. The Food and Drug Administration (FDA) has flexibility in how it applies this standard.The authors conducted a systematic literature review of studies evaluating the design and outcomes of the key trials supporting new drug approvals in the United States. They extracted data on the trial characteristics, endpoint types, and expedited regulatory pathways.Among 48 publications eligible for inclusion, 30 covered trial characteristics, 23 covered surrogate measures, and 30 covered regulatory pathways. Trends point toward less frequent randomization, double-blinding, and active controls, with variation by drug type and indication. Surrogate measures are becoming more common but are not consistently well correlated with clinical outcomes. Drugs approved through expedited regulatory pathways often have less rigorous trial design characteristics.The characteristics of trials used to approve new drugs have evolved over the past two decades along with greater use of expedited regulatory pathways and changes in the nature of drugs being evaluated. While flexibility in regulatory standards is important, policy changes can emphasize high-quality data collection before or after FDA approval." @default.
• W4286563749 created "2022-07-22" @default.
• W4286563749 creator A5008840484 @default.
• W4286563749 creator A5036726043 @default.
• W4286563749 creator A5038281235 @default.
• W4286563749 creator A5050824232 @default.
• W4286563749 creator A5067101426 @default.
• W4286563749 creator A5073176239 @default.
• W4286563749 creator A5074257304 @default.
• W4286563749 creator A5088259612 @default.
• W4286563749 date "2022-07-14" @default.
• W4286563749 modified "2023-10-16" @default.
• W4286563749 title "Trends in the Quality of Evidence Supporting FDA Drug Approvals: Results from a Literature Review" @default.
• W4286563749 cites W1810662963 @default.
• W4286563749 cites W1857884548 @default.
• W4286563749 cites W1966768512 @default.
• W4286563749 cites W2007422794 @default.
• W4286563749 cites W2030295061 @default.
• W4286563749 cites W2087056834 @default.
• W4286563749 cites W2099754848 @default.
• W4286563749 cites W2101073224 @default.
• W4286563749 cites W2107120363 @default.
• W4286563749 cites W2109314733 @default.
• W4286563749 cites W2130434619 @default.
• W4286563749 cites W2140922502 @default.
• W4286563749 cites W2151333691 @default.
• W4286563749 cites W2155598961 @default.
• W4286563749 cites W2188787431 @default.
• W4286563749 cites W2200963198 @default.
• W4286563749 cites W2239807184 @default.
• W4286563749 cites W2247744236 @default.
• W4286563749 cites W2397053700 @default.
• W4286563749 cites W2418190818 @default.
• W4286563749 cites W2464447852 @default.
• W4286563749 cites W2482872313 @default.
• W4286563749 cites W2531470489 @default.
• W4286563749 cites W2570638120 @default.
• W4286563749 cites W2582472002 @default.
• W4286563749 cites W2612600212 @default.
• W4286563749 cites W2623751563 @default.
• W4286563749 cites W2737584688 @default.
• W4286563749 cites W2746717271 @default.
• W4286563749 cites W2777434883 @default.
• W4286563749 cites W2793539832 @default.
• W4286563749 cites W2800553228 @default.
• W4286563749 cites W2802689544 @default.
• W4286563749 cites W2802698237 @default.
• W4286563749 cites W2811203720 @default.
• W4286563749 cites W2884562717 @default.
• W4286563749 cites W2885935551 @default.
• W4286563749 cites W2890763753 @default.
• W4286563749 cites W2907166494 @default.
• W4286563749 cites W2912386223 @default.
• W4286563749 cites W2934647261 @default.
• W4286563749 cites W2945931600 @default.
• W4286563749 cites W2947203714 @default.
• W4286563749 cites W2947409284 @default.
• W4286563749 cites W2947583588 @default.
• W4286563749 cites W2990091274 @default.
• W4286563749 cites W2996636952 @default.
• W4286563749 cites W2998984898 @default.
• W4286563749 cites W3007239545 @default.
• W4286563749 cites W3017195870 @default.
• W4286563749 cites W3018686791 @default.
• W4286563749 cites W3020205041 @default.
• W4286563749 cites W3035278090 @default.
• W4286563749 cites W3044069777 @default.
• W4286563749 cites W3046028078 @default.
• W4286563749 cites W3091508116 @default.
• W4286563749 cites W3098856567 @default.
• W4286563749 cites W3106002557 @default.
• W4286563749 doi "https://doi.org/10.1215/03616878-10041093" @default.
• W4286563749 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35867548" @default.
• W4286563749 hasPublicationYear "2022" @default.
• W4286563749 type Work @default.
• W4286563749 citedByCount "2" @default.
• W4286563749 countsByYear W42865637492022 @default.
• W4286563749 countsByYear W42865637492023 @default.
• W4286563749 crossrefType "journal-article" @default.
• W4286563749 hasAuthorship W4286563749A5008840484 @default.
• W4286563749 hasAuthorship W4286563749A5036726043 @default.
• W4286563749 hasAuthorship W4286563749A5038281235 @default.
• W4286563749 hasAuthorship W4286563749A5050824232 @default.
• W4286563749 hasAuthorship W4286563749A5067101426 @default.
• W4286563749 hasAuthorship W4286563749A5073176239 @default.
• W4286563749 hasAuthorship W4286563749A5074257304 @default.
• W4286563749 hasAuthorship W4286563749A5088259612 @default.
• W4286563749 hasBestOaLocation W42865637491 @default.
• W4286563749 hasConcept C105795698 @default.
• W4286563749 hasConcept C112930515 @default.
• W4286563749 hasConcept C126322002 @default.
• W4286563749 hasConcept C148482608 @default.
• W4286563749 hasConcept C177713679 @default.
• W4286563749 hasConcept C2771230 @default.
• W4286563749 hasConcept C2780035454 @default.
• W4286563749 hasConcept C2780598303 @default.
• W4286563749 hasConcept C2992293740 @default.
• W4286563749 hasConcept C3018890749 @default.

• next